Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging drugs for renal failure.

Prabal K Chatterjee1, Christoph Thiemermann

  • 1Department of Pharmacology, School of Pharmacy & Biomolecular Sciences, University of Brighton, Cockcroft Building, Moulsecoomb, Brighton, BN2 4GJ, UK. p.k.chatterjee@brighton.ac.uk

Expert Opinion on Emerging Drugs
|December 10, 2003
PubMed
Summary

Renal failure, both acute and chronic, impairs kidney function, potentially leading to end-stage disease. Current treatments manage risks and consequences, but novel therapies are needed for better prevention and management of kidney failure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: IkB Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD.

Journal of the American Society of Nephrology : JASN·2026
Same author

RETRACTED: "Evidence for the Role of Peroxisome Proliferator-Activated Receptor- β/δ in the Development of Spinal Cord Injury".

The Journal of pharmacology and experimental therapeutics·2026
Same author

Retraction Note: Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Retraction Note: Targeting the NLRP3 inflammasome to reduce diet-induced metabolic abnormalities in mice.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Targeting immunometabolic pathways with AZD1656 alleviates inflammation and metabolic dysfunction in type 2 diabetic cardiomyopathy.

Nature cardiovascular research·2026
Same author

Artesunate alleviates kidney fibrosis by restoring klotho protein and suppressing Wnt/β-catenin signalling pathway.

Frontiers in cell and developmental biology·2025

Area of Science:

  • Nephrology
  • Pharmacology
  • Internal Medicine

Background:

  • Renal failure, encompassing acute (ARF) and chronic (CRF) forms, signifies impaired kidney function.
  • While ARF may be reversible, CRF is typically irreversible, both potentially progressing to end-stage renal disease (ESRD).
  • ESRD necessitates renal replacement therapy (RRT), such as dialysis or transplantation, which is complex and costly.

Purpose of the Study:

  • To review current therapies for adult renal failure prevention and management.
  • To detail emerging drugs and novel interventions for treating or preventing ESRD.

Main Methods:

  • Review of existing pharmacological interventions for CRF risk factors and consequences.
  • Analysis of recent evidence on anti-inflammatory effects of certain treatments.

Related Experiment Videos

  • Description of novel therapeutic agents and interventions in development.

    • Main Results:

    • Current CRF drugs manage risk factors (e.g., ACE inhibitors, statins) or consequences (e.g., erythropoietin, calcitriol).
    • Some interventions show promise in reducing renal inflammation, a key factor in CRF progression.
    • Despite improvements, novel therapies are crucial for better outcomes in ESRD.

    Conclusions:

    • Existing therapies improve outcomes for renal failure but do not offer a cure.
    • Emerging drugs and novel interventions hold promise for improved prevention and treatment of ESRD.
    • Continued research into innovative therapies is essential for managing renal failure and ESRD.